UPLOAD Filing
MBX Biosciences, Inc.
Date: Aug. 13, 2025 · CIK: 0001776111 · Accession: 0000000000-25-008532
AI Filing Summary & Sentiment
Reasoning
Letter
Re: MBX Biosciences, Inc. Draft Registration Statement on Form S-1 Submitted August 8, 2025 CIK No. 0001776111 Dear P. Kent Hawryluk:
August 13, 2025
P. Kent Hawryluk Chief Executive Officer MBX Biosciences, Inc. 11711 N. Meridian Street, Suite 300 Carmel, IN 46032
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Edwin O Connor, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 13, 2025 P. Kent Hawryluk Chief Executive Officer MBX Biosciences, Inc. 11711 N. Meridian Street, Suite 300 Carmel, IN 46032 Re: MBX Biosciences, Inc. Draft Registration Statement on Form S-1 Submitted August 8, 2025 CIK No. 0001776111 Dear P. Kent Hawryluk: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Edwin O Connor, Esq. </TEXT> </DOCUMENT>